U.S. markets close in 1 hour 58 minutes
  • S&P 500

    4,416.02
    +4.23 (+0.10%)
     
  • Dow 30

    35,107.90
    +46.35 (+0.13%)
     
  • Nasdaq

    14,824.91
    -12.08 (-0.08%)
     
  • Russell 2000

    2,210.85
    +1.20 (+0.05%)
     
  • Crude Oil

    71.91
    -0.16 (-0.22%)
     
  • Gold

    1,798.50
    -3.30 (-0.18%)
     
  • Silver

    25.30
    +0.07 (+0.27%)
     
  • EUR/USD

    1.1815
    +0.0044 (+0.38%)
     
  • 10-Yr Bond

    1.2710
    -0.0150 (-1.17%)
     
  • GBP/USD

    1.3821
    +0.0067 (+0.49%)
     
  • USD/JPY

    110.3300
    -0.1800 (-0.16%)
     
  • BTC-USD

    39,200.05
    +4,767.22 (+13.84%)
     
  • CMC Crypto 200

    934.28
    +18.79 (+2.05%)
     
  • FTSE 100

    7,025.43
    -2.15 (-0.03%)
     
  • Nikkei 225

    27,833.29
    +285.29 (+1.04%)
     

G1 Therapeutics to Participate in Evercore ISI 2nd Annual HealthCONx Conference on December 4, 2019

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will participate in a fireside chat at the Evercore ISI 2nd Annual HealthCONx Conference. The fireside chat will take place on Wednesday, December 4, 2019 at 4:35 p.m. at the Boston Four Seasons Hotel in Boston, MA.

To access the live webcast, please visit the Events & Presentations page within the Investors section of the G1 website. The webcast will be archived on the same page for 90 days following the event.

About G1 Therapeutics
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is advancing three clinical-stage programs. Trilaciclib is a first-in-class therapy designed to improve outcomes for patients being treated with chemotherapy. Trilaciclib has received Breakthrough Therapy Designation from the FDA; a rolling NDA submission for small cell lung cancer will begin in 4Q19 and is expected to be completed in the second quarter of 2020. Lerociclib is a differentiated oral CDK4/6 inhibitor designed to enable more effective combination treatment strategies. G1T48 is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. G1 Therapeutics also has an active discovery program focused on cyclin-dependent kinase targets.

G1 is based in Research Triangle Park, NC. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

Contact:
Jeff Macdonald
Senior Director, Investor Relations & Corporate Communications
919-907-1944
jmacdonald@g1therapeutics.com